Phase I/II trial of Abraxane (ABI-007) [paclitaxel] and Alimta (pemetrexed) in advanced solid tumors with emphasis on non-small cell lung cancer (NSCLC) and breast cancer

Trial Profile

Phase I/II trial of Abraxane (ABI-007) [paclitaxel] and Alimta (pemetrexed) in advanced solid tumors with emphasis on non-small cell lung cancer (NSCLC) and breast cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Pemetrexed (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2017 Status changed from completed to discontinued.
    • 16 Nov 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top